How is digital technology transforming the emerging patient-centric paradigm?
Patient-centered care is often referred to in the context of traditional healthcare, but scientists at MedImmune will tell you: Focusing on improving the patient journey – from earlier diagnosis to integrated and/or targeted assessment – is, and has been, a top priority.
MedImmune isn’t alone. Much of the biotech industry is shifting away from the “one-size-fit-all” approach to drug development, and a patient centric paradigm is emerging – notably with the rise of data collected from non-traditional methods in the real-world setting and better ways to analyze that data.
But exactly how are digital technologies transforming this new paradigm, particularly patients’ and drug developers’ understanding of diseases and treatment options?
On October 9, 2018, MedImmune hosted a one-day Translational Science Forum in the Bay Area, gathering academic institutions, industry leaders, and other experts in the drug development ecosystem to assess this critical question.
If you missed the event, here’s the top takeaways and findings from a roster of expert speakers:
https://lnkd.in/gwfRsia
MedImmune isn’t alone. Much of the biotech industry is shifting away from the “one-size-fit-all” approach to drug development, and a patient centric paradigm is emerging – notably with the rise of data collected from non-traditional methods in the real-world setting and better ways to analyze that data.
But exactly how are digital technologies transforming this new paradigm, particularly patients’ and drug developers’ understanding of diseases and treatment options?
On October 9, 2018, MedImmune hosted a one-day Translational Science Forum in the Bay Area, gathering academic institutions, industry leaders, and other experts in the drug development ecosystem to assess this critical question.
If you missed the event, here’s the top takeaways and findings from a roster of expert speakers:
https://lnkd.in/gwfRsia
